RxSight, Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 8, 2022

Rhea-AI Summary

RxSight, Inc. (NASDAQ: RXST) announced it will release its financial results for the fourth quarter and fiscal year 2021 on March 8, 2022, after market close. A conference call with management will follow at 1:30 p.m. PT to discuss the results. The company specializes in ophthalmic medical devices aimed at enhancing post-cataract surgery vision through its innovative Light Adjustable Lens (LAL) system. This technology includes unique features like ActivShield™ for UV protection.

Positive

• RxSight's proprietary Light Adjustable Lens system offers enhanced customization for post-cataract surgery vision.
• The LAL technology includes ActivShield™, a UV protection layer, aligning with patient safety and quality.

Negative

• None.

ALISO VIEJO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the fourth quarter and fiscal year 2021 after the market close on Tuesday, March 8, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. The call will also be available by dialing 844-602-7038 (U.S.) or 916-637-9714 (International) five to ten minutes prior to the start time, using conference ID: 8478727.

About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight^® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens^® (LAL^®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
415.937.5406
IR@rxsight.com

Company contact:
Shelley Thunen
Chief Financial Officer
ir@rxsight.com

 

FAQ

What is the date RxSight will report its fourth quarter and fiscal year 2021 financial results?

RxSight will report its financial results on March 8, 2022, after market close.

What time is the conference call to discuss RxSight's financial results scheduled?

The conference call is scheduled for 1:30 p.m. Pacific Time on March 8, 2022.

Where can I listen to the RxSight financial results conference call?

You can access the live and archived webcast of the conference call on RxSight's Investors page at www.rxsight.com.

What technology does RxSight offer for cataract surgery patients?

RxSight offers the Light Adjustable Lens (LAL) system, which allows customization and optimization of visual acuity after cataract surgery.